Conbercept Ophthalmic Injection for Patients With Macular Edema Caused by Branch Retinal Vein Occlusion (BRAVE)
Multi-center, Randomized, Double-masked, Placebo-controlled Phase III Clinical Study of Conbercept Ophthalmic Injection for Patients With BRVO.
Sponsor: Chengdu Kanghong Biotech Co., Ltd.
A PHASE3 clinical study on Branch Retinal Vein Occlusion and Macular Edema, this trial is completed. The trial is conducted by Chengdu Kanghong Biotech Co., Ltd. and has accumulated 9 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE3
Status: Unknown Status → Completed
-
Jan 2021 — Sep 2022 [monthly]
Unknown Status PHASE3
Status: Recruiting → Unknown Status
▶ Show 4 earlier versions
-
Feb 2019 — Jan 2021 [monthly]
Recruiting PHASE3
-
Oct 2018 — Feb 2019 [monthly]
Recruiting PHASE3
-
Jun 2018 — Oct 2018 [monthly]
Recruiting PHASE3
-
May 2017 — Jun 2018 [monthly]
Recruiting PHASE3
First recorded
Apr 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Chengdu Kanghong Biotech Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beijing, China , Changchun, China , Changsha, China , Chengdu, China , Chongqing, China , Dalian, China , Guangzhou, China , Hangzhou, China , Harbin, China , Nanchang, China and 11 more locations